Clinical Trials, Petitions, and Upcoming Earnings Releases - Analyst Notes on Celgene, Covidien, AbbVie, Teva and Thermo Fisher Scientific

Tue Jul 8, 2014 5:40am EDT

* Reuters is not responsible for the content in this press release.

Clinical Trials, Petitions, and Upcoming Earnings Releases - Analyst Notes on Celgene, Covidien, AbbVie, Teva and Thermo Fisher Scientific

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, July 8, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Covidien plc (NYSE: COV), AbbVie Inc (NYSE: ABBV), Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and Thermo Fisher Scientific Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at:

Celgene Corporation Analyst Notes
On July 3, 2014, the stock of Celgene Corporation (Celgene) gained 0.13% to close at $90.19. Over the past one month of trading, Celgene's stock increased 15.99%, while the Nasdaq Composite gained 5.95% during the same period. The full analyst notes on Celgene are available to download free of charge at:

Covidien plc Analyst Notes
On June 26, 2014, Covidien plc (Covidien) informed that it will release its Q3 FY 2014 results on July 25, 2014. A conference call for investors hosted by the Company will also take place on the same day at 8:30 a.m. The full analyst notes on Covidien are available to download free of charge at:

AbbVie Inc Analyst Notes
On June 26, 2014, AbbVie Inc (AbbVie) announced the start of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), when added to carboplatin and paclitaxel, two chemotherapeutic medicines, in patients with advanced breast cancer. According to the Company, the study will target the effects of the combination of veliparib, carboplatin and paclitaxel in patients with human epidermal growth factor receptor 2-(HER2) negative metastatic or locally-advanced breast cancer, containing BRCA1 and/or BRCA2 gene mutations, compared to treatment with carboplatin, paclitaxel and placebo. An approximate 270 patients will be recruited for this randomized, double-blind, Phase III clinical trial. The full analyst notes on AbbVie are available to download free of charge at:

Teva Pharmaceutical Industries Ltd Analyst Notes
On July 3, 2014, Teva Pharmaceutical Industries Ltd (Teva) announced the filing of a citizen petition (CP) in relation to the purported generic versions of COPAXONE®. The CP was submitted according to the FDA's procedural guidance and in accordance with the Agency's desire to facilitate public review and comment regarding new scientific data on gene expression. According to the Company, its CP provides new scientific data on gene expression and evidence to support arguments regarding active ingredient sameness, immunogenicity and bioequivalence testing with regard to its relapsing-remitting multiple sclerosis medicine, COPAXONE®. Further, Teva stated that it would be contrary to the public's health and welfare to approve a purported generic glatiramer acetate product that, based on current analytical technologies and confirmed by techniques such as gene expression evaluation, at best can be shown to be similar, but clearly not the same as, COPAXONE®. The full analyst notes on Teva are available to download free of charge at:

Thermo Fisher Scientific Inc. Analyst Notes
On July 2, 2014, Thermo Fisher Scientific Inc (Thermo Fisher Scientific) announced that its Q2 2014 financial results will be issued on Wednesday, July 23, 2014, prior to market opening. A conference call to discuss the results will follow at 8:30 a.m. EDT on the same day. Interested parties may access the call by logging on to Thermo Fisher Scientific's website. The full analyst notes on Thermo Fisher Scientific are available to download free of charge at:

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at]

5. For any urgent concerns or inquiries, please contact us at compliance [at]

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] for consideration.

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review